Capricorn Fund Managers Ltd Acquires Shares of 50,000 Astera Labs, Inc. $ALAB

Capricorn Fund Managers Ltd acquired a new stake in Astera Labs, Inc. (NASDAQ:ALAB) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 50,000 shares of the company’s stock, valued at approximately $8,318,000. Astera Labs makes up 2.0% of Capricorn Fund Managers Ltd’s holdings, making the stock its 13th biggest holding.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Assetmark Inc. grew its stake in Astera Labs by 374.1% in the 3rd quarter. Assetmark Inc. now owns 128 shares of the company’s stock valued at $25,000 after acquiring an additional 101 shares during the period. Hilltop National Bank raised its position in Astera Labs by 100.0% during the fourth quarter. Hilltop National Bank now owns 200 shares of the company’s stock worth $33,000 after acquiring an additional 100 shares during the period. Aventura Private Wealth LLC acquired a new position in Astera Labs during the fourth quarter worth $33,000. Wexford Capital LP purchased a new position in Astera Labs during the third quarter valued at $39,000. Finally, National Bank of Canada FI grew its position in shares of Astera Labs by 159.0% in the third quarter. National Bank of Canada FI now owns 202 shares of the company’s stock valued at $39,000 after purchasing an additional 124 shares during the period. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Insider Transactions at Astera Labs

In other Astera Labs news, General Counsel Philip Mazzara sold 10,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $107.77, for a total value of $1,077,700.00. Following the transaction, the general counsel directly owned 118,084 shares in the company, valued at $12,725,912.68. The trade was a 7.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Manuel Alba sold 183,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $107.61, for a total transaction of $19,692,630.00. Following the completion of the sale, the director directly owned 319,863 shares of the company’s stock, valued at approximately $34,420,457.43. This trade represents a 36.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 577,292 shares of company stock valued at $69,495,249 in the last three months. 12.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Citigroup assumed coverage on shares of Astera Labs in a research note on Thursday. They set a “buy” rating and a $200.00 target price for the company. Northland Securities lifted their price objective on Astera Labs from $175.00 to $195.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. Royal Bank Of Canada initiated coverage on Astera Labs in a research note on Wednesday, January 14th. They set an “outperform” rating and a $225.00 price objective for the company. Loop Capital began coverage on Astera Labs in a report on Thursday, March 5th. They set a “buy” rating and a $250.00 target price for the company. Finally, Weiss Ratings downgraded Astera Labs from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, February 23rd. Fifteen research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $199.44.

More Astera Labs News

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Citi initiated/maintained a Buy and set a $200 price target on ALAB, highlighting PCIe and AI-infrastructure opportunity — a sizable analyst endorsement that can lift sentiment and buying interest. Benzinga Coverage
• Positive Sentiment: Research notes (TipRanks summary) underscore Astera Labs’ PCIe switch leadership and positioning in rack-scale AI connectivity, framing multiyear revenue upside tied to data-center AI buildouts. Astera Labs: Leveraging PCIe Switch Leadership…
• Positive Sentiment: Astera appears on roundups of leading growth stocks with notable insider ownership — a signal some investors use to judge management alignment and conviction, which can support valuation multiple expansion if execution continues. April 2026’s Leading Growth Stocks With Insider Ownership
• Neutral Sentiment: Company announced it will report Q1 2026 results after market close on May 5 and hold a conference call — an imminent catalyst that could swing the stock depending on revenue, margins and guidance. Astera Labs Announces Conference Call…
• Negative Sentiment: Recent articles flag a ~36% YTD decline and call out margin pressure and intensifying competition as key near-term risks; these concerns help explain the share-price pullback despite top-line AI/PCIe tailwinds. Should You Hold on to Astera Labs Stock Despite Its 36% Dip in YTD?
• Negative Sentiment: Analyst commentary and newsletter pieces emphasize margin compression risks even as demand grows — if margins miss or competition accelerates, upside expectations tied to AI/PCIe could be delayed. Should You Hold on to Astera Labs Stock Despite Its 36% Dip in YTD? (Zacks)

Astera Labs Stock Performance

Shares of Astera Labs stock opened at $117.14 on Monday. The business’s 50 day moving average price is $131.56 and its 200 day moving average price is $158.45. The company has a market cap of $20.06 billion, a price-to-earnings ratio of 96.02, a PEG ratio of 2.31 and a beta of 1.78. Astera Labs, Inc. has a one year low of $47.13 and a one year high of $262.90.

Astera Labs (NASDAQ:ALAB) last issued its earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.07. Astera Labs had a return on equity of 16.12% and a net margin of 25.70%.The company had revenue of $270.58 million during the quarter, compared to analysts’ expectations of $249.46 million. During the same period in the prior year, the business earned $0.37 EPS. The firm’s quarterly revenue was up 91.8% on a year-over-year basis. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. On average, analysts predict that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.